Press release content from News Direct Corporation. The AP news staff was not involved in its creation.
Poolbeg Pharma identifies new RSV drug candidates
PRESS RELEASE: Paid content from News Direct Corporation
Press release content from News Direct Corporation. The AP news staff was not involved in its creation.December 22, 2022 GMT
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing that Poolbeg has identified several potential candidates from its Respiratory Syncytial Virus (RSV) AI collaboration with One Three Biotech. He also looks back on what the company achieved during 2022 and looks ahead to what investors can expect from Poolbeg in 2023.
Proactive UK Ltd
+44 20 7989 0813
View original content to download multimedia: https://newsdirect.com/news/poolbeg-pharma-identifies-new-rsv-drug-candidates-240574752